The Globe and Mail reports in its Saturday edition that the latest stock market craze is upon us. The Globe's Tim Shufelt writes that a new class of obesity and diabetes drugs known as GLP-1s is being hyped as the weight-loss Holy Grail the pharmaceutical industry has chased for decades. Great fortunes are already being realigned within the pharmaceutical sector and beyond, which Mr. Shufelt calls the Ozempic Effect. Is it overdone? Mr. Shufelt asks. Of course. Many of the hallmarks of a stock bubble are there. Novo Nordisk, the Danish firm behind the Ozempic shot for Type 2 diabetes and the Wegovy weight loss shot, as well as Eli Lilly, whose drug Zepbound was approved by the Food and Drug Administration on Wednesday, have each seen their stock rise by more than 60 per cent over the past year. Forty per cent of the U.S. population is classified as obese. Big Pharma names on the sidelines of the GLP-1 wave, such as Merck and Pfizer, are all nursing losses on the year, as investors have shifted their health care exposure to the sector's hottest trade. And in the apparent expectation that GLP-1 drugs will reshape the eating habits of a nation, investors have traded down the shares of Kraft Heinz, Hershey and Coca-Cola.